JEREMY BENDER, PHD, MBA

Jeremy Bender, Ph.D., M.B.A. has served on our Board since October 2023.  Since September 2020 he has served as Chief Executive Officer, President and a member of the board of directors of Day One Biopharmaceuticals, Inc., a biotechnology company focused on developing new medicines for patients of all ages living with cancer.  Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences from March 2018 to September 2020. He held several leadership roles in biotech companies prior to Gilead, including Chief Operating Officer of  Tizona Therapeutics from July 2015 to March 2018, Chief Business Officer of Sutro Biopharma from October 2012 to July 2015, and Vice President of Corporate Development at Allos Therapeutics, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. He holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.